Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectra7 Announces Production Shipments for Medical Augmented Reality Pioneer eSight

V.SEV

High-Resolution and Low-Latency Display Data is Enabled on Ultra-Thin Cable by Spectra7

PALO ALTO, CA --(Marketwired - March 13, 2017) - (TSX: SEV) Spectra7 Microsystems Inc. ("Spectra7" or the "Company"), a leading provider of high-performance analog semiconductor products for virtual reality (VR), augmented reality (AR), data center and other connectivity markets today announced its collaboration with eSight Corporation. eSight produces electronic glasses that enable the legally blind to actually see, and also boasts the largest, most knowledgeable and well-funded research and development lab in the world dedicated to wearable, sight-restoring technologies. Spectra7 has been working with the revolutionary eyewear company for over a year to develop two different solutions using Spectra7's patented active cable technology, which were officially launched by eSight earlier this month.

"As a company we are proud to support eSight and their mission that everyone deserves to see. The technology is life-changing and we are thrilled to be a part of it," said Spectra7 CEO, Raouf Halim.

eSight's breakthrough device combines the strengths of AR and VR technology to help individuals living with legal blindness and low-vision to see, and their patented Bioptic Tilt feature allows users to be completely mobile. eSight's eyewear provides real-time, low-latency, high-definition video and image processing that goes beyond the video quality found in typical AR and VR devices. The viewer sees an amplified and focused view of the world around them, sometimes for the first time in years, or ever, allowing for an active, independent and productive lifestyle.

According to the World Health Organization, 285 million people are estimated to be visually impaired worldwide. 80% of all visual impairment can be improved, using devices like the eSight 3, in addition to traditional sight improvement methods.

"Spectra7's unique cable technology allows an eSight user to view what is in front of them in high-definition, while providing a thin, flexible interconnect cable to the eSight controller," said Dr. Brian Mech, President & CEO of eSight. "More importantly, their advanced cable technology is a key part of eSight that allows us to achieve enhanced vision with virtually no latency in our displays, avoiding issues of imbalance or nausea common with other immersive options."

eSight just recently released "eSight 3," their lightest, most affordable glasses to date. eSight 3 has been featured in stories by USA Today, Fox News, CNBC, and other major US and international news outlets.

ABOUT SPECTRA7 MICROSYSTEMS INC.

Spectra7 Microsystems Inc. is a high performance analog semiconductor company delivering unprecedented bandwidth, speed and resolution to enable disruptive industrial design for leading electronics manufacturers in virtual reality, augmented reality, data centers and other connectivity markets. Spectra7 is based in Palo Alto, California with design centers in Markham, Ontario, Cork, Ireland, and Little Rock, Arkansas. For more information, please visit www.spectra7.com.

ABOUT ESIGHT

eSight was founded in 2006 for the sole purpose of allowing legally blind and low vision people to see. eSight is an ISO-9001:2015 certified manufacturer, with locations in Los Angeles, Toronto, Ottawa, and a network of affiliates across the United States. This unique patented assistive device enables people with vision loss to actually see and independently carry out virtually all Activities of Daily Living. eSight can help a worldwide population of several hundred million people with conditions including, but not limited to, Macular Degeneration, Diabetic Retinopathy, Stargardt Disease, Ocular Albinism, Optic Nerve Hypoplasia, Leber's Hereditary Optic Neuropathy, Cone-Rod Dystrophy, Nystagmus, Retinopathy of Prematurity, and some forms of Glaucoma and Retinitis Pigmentosa. eSight is registered with the FDA and Health Canada.

To learn more about eSight, visit www.eSightEyewear.com or call 1-855-837-4448.

CAUTIONARY NOTES

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's future financial position and results of operations, strategy, proposed acquisitions, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's annual MD&A for the year ended December 31, 2016. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.

For more information, please contact:

Spectra7 Microsystems Inc.
Sean Peasgood
Investor Relations
416-565-2805
ir@spectra7.com

Spectra7 Microsystems Inc.
David Mier
Chief Financial Officer
925.858.7011
pr@spectra7.com

Spectra7 Microsystems Inc.
Rob Chalmers
Capital Markets
647-402-7552
ir@spectra7.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today